Clinical Trials Logo

Refractory AML clinical trials

View clinical trials related to Refractory AML.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03516760 Terminated - Clinical trials for Acute Myeloid Leukemia

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

Start date: April 11, 2018
Phase: Phase 1
Study type: Interventional

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.